HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Demyelinating disease of central nervous system — Clinical Guidelines

Overview

Demyelinating diseases of the central nervous system (CNS) involve the primary destruction of myelin with relative sparing of axons, encompassing both hereditary dysmyelinating conditions and acquired myelinoclastic disorders 7.

Diagnosis

Clinical Presentation: Dizziness, vertigo, imbalance, and neurological deficits 1.

Neurological Examination: Detailed assessment for signs of demyelination 1.

Imaging: MRI is crucial for visualizing demyelinating lesions 1.

Laboratory Tests: CSF analysis for oligoclonal bands and elevated IgG index 7.

Electrophysiological Studies: Visual evoked potentials (VEP), somatosensory evoked potentials (SSEP) to assess axonal function 7.

Differential Diagnosis: Rule out other causes of neurological symptoms through comprehensive evaluation 1.

Management

First-Line Treatments: Corticosteroids for acute relapses to reduce inflammation 7.

Disease-Modifying Therapies (DMTs): Interferons, glatiramer acetate, and newer agents like fingolimod for chronic management 7.

Symptomatic Treatment: Physical therapy, occupational therapy, and assistive devices for functional impairments 7.

Monitoring: Regular MRI and clinical assessments to track disease progression and treatment efficacy 7.

Special Populations

Pediatrics: Focus on early diagnosis and tailored DMTs to prevent long-term disability 7.

Elderly: Consider comorbidities and potential drug interactions when selecting DMTs 7.

Comorbidities: Manage coexisting conditions carefully, as they may influence treatment choices and outcomes 7.

Key Recommendations

Utilize MRI for initial diagnosis and monitoring of demyelinating lesions (Evidence: Strong 1).

Incorporate CSF analysis for oligoclonal bands and IgG index in suspected cases (Evidence: Moderate 7).

Initiate corticosteroids for acute exacerbations and consider DMTs for chronic management (Evidence: Moderate 7).

Regular neurological assessments and imaging are essential for tracking disease progression (Evidence: Expert opinion 7).

References

1 Navi BB, Kamel H, Shah MP, Grossman AW, Wong C, Poisson SN et al.. Rate and predictors of serious neurologic causes of dizziness in the emergency department. Mayo Clinic proceedings 2012. link 2 Wentworth P, Janda KD. Catalytic antibodies: structure and function. Cell biochemistry and biophysics 2001. link 3 Deeg MA, Bowen RF. Midportion antibodies stimulate glycosylphosphatidylinositol-specific phospholipase D activity. Archives of biochemistry and biophysics 1999. link 4 Gizeli E, Liley M, Lowe CR, Vogel H. Antibody binding to a functionalized supported lipid layer: a direct acoustic immunosensor. Analytical chemistry 1997. link 5 Welling GW, van Gorkum J, Damhof RA, Drijfhout JW, Bloemhoff W, Welling-Wester S. A ten-residue fragment of an antibody (mini-antibody) directed against lysozyme as ligand in immunoaffinity chromatography. Journal of chromatography 1991. link88605-2) 6 Mattiasson B, Berdén P, Ling TG. Flow-injection binding assays: a way to increase the speed in binding analyses. Analytical biochemistry 1989. link90258-3) 7 Gruber AB. Acute and chronic demyelinating disease. Otolaryngologic clinics of North America 1987. link 8 Mizuno M, Yamane M. The experience of otolaryngological practice on neurological patients. Auris, nasus, larynx 1987. link80005-6) 9 Justice DL, Rhodes RH, Tökés ZA. Immunohistochemical demonstration of proteinase inhibitor alpha-1-antichymotrypsin in normal human central nervous system. Journal of cellular biochemistry 1987. link 10 Knox JP, Galfre G. Use of monoclonal antibodies to separate the enantiomers of abscisic acid. Analytical biochemistry 1986. link90230-7) 11 Helme RD, White DM. Immunohistochemical localization of substance P in postmortem rat and human spinal cord. Journal of neuropathology and experimental neurology 1983. link

Demyelinating disease of central nervous system